NGF and lip and oral cavity carcinoma: For oral cancer in animal models, anti-NGF mAbs impair the proper activation of NGF, decrease the volume of tumour lesions and relieve weight loss, accompanied by decreased levels of nociceptive receptors (Ye et al. 2011).